Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1244 • ACR Convergence 2022
Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Ann-Sophie Kathleen De Craemer³, Serge Steinfeld⁴, Adrien NZEUSSEU TOUKAP⁵, Filip Van den bosch⁶, Dirk Elewaut⁷, Rik Lories⁸ and Kurt de Vlam⁹, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Ghent University Hospital, Gent, Belgium, ⁴Clinique Saint-Jean, Brussels, Belgium, ⁵Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁷Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁸KU Leuven, Leuven, Belgium, ⁹University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA) patients. This study reports the baseline radiographic spinal damage in PsA and…
Abstract Number: 1500 • ACR Convergence 2022
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
John Koussiouris¹, Nikita Looby², Max Kotlyar³, Vathany Kulasingam⁴, Igor Jurisica⁵ and Vinod Chandran⁶, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute/ Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto/ Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network/ Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada, ⁶Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease that affects over 7.25 million Americans and 1.25 million Canadians. Approximately 25% of psoriasis patients, have an inflammatory…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 2115 • ACR Convergence 2022
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Laura Coates¹, Julio Ramírez², Dennis McGonagle³, Sibel Aydin⁴, Miriam Zimmermann⁵, Francois Nantel⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Peter Nash⁹ and Philip J Mease¹⁰, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁶Nantel MedSci Consult, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…
Abstract Number: 2132 • ACR Convergence 2022
Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Roy Fleischmann¹, Diamant Thaci², Melinda Gooderham³, Bruce Strober⁴, Neil J. Korman⁵, Subhashis Banerjee⁶, Tom Lehman⁶, Miroslawa Nowak⁶, Antoine Sreih⁷, Akimichi Morita⁸ and Philip J Mease⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ³SKiN Centre for Dermatology, Queen’s University, Probity Medical Research, Peterborough, Canada, ⁴Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ⁵Case Western Reserve University and University Hospitals, Cleveland, OH, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Philadelphia, PA, ⁸Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK)…
Abstract Number: 2149 • ACR Convergence 2022
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Francisca Guimarães¹, Maria Pontes-Ferreira¹, Catarina Soares¹, Hugo Parente², Carolina Ochôa Matos³, Roberto Costa³, Daniela Oliveira⁴, Catarina Abreu⁵, Rafaela teixeira⁶, Sofia Ferreira Azevedo⁷, João Madruga-Dias⁸, Filipe Araújo⁹, Carla Campinho Ferreira¹⁰, Daniela Santos-Faria² and José Tavares-Costa², ¹Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ²Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal, ⁵Rheumatology Department, Hospital Garcia de Orta, Lisboa, Portugal, ⁶Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ⁹Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ¹⁰Rheumatology Department, Hospital de Braga, Braga, Portugal
Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…
Abstract Number: 0212 • ACR Convergence 2022
Managing Psoriatic Arthritis: Patients’ Views and Attitudes to Using an Online Wellness Program
Angela Degrassi¹, William Benjamin Nowell², Shilpa Venkatachalam³, Kelly Gavigan¹, Ashley Krivohlavek⁴, Esteban Rivera¹ and M. Elaine Husni⁵, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Claremore, OK, ⁵Cleveland Clinic, Cleveland, OH
Background/Purpose: Patients diagnosed with psoriatic arthritis (PsA) confront decisions about how to optimize treatment of their chronic disease including patient physician interaction and modifying their…
Abstract Number: 0509 • ACR Convergence 2022
Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Jeffrey Curtis¹, Iain B McInnes², Proton Rahman³, Dafna Gladman⁴, Feifei Yang⁵, Steve Peterson⁵, Alexa Kollmeier⁶, Natalie Shiff⁷, Chenglong Han⁸, May Shawi⁹, William Tillett¹⁰ and Philip J Mease¹¹, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ³Memorial University, St. John's, NL, Canada, ⁴Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Department of Immunology, Janssen Global Services, LLC, Horsham, PA, ⁶Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) impacts patients' work productivity (WP) and daily activity.1 DISCOVER-2 (D2), a phase 3 trial of the selective interleukin-23 p19-subunit inhibitor guselkumab…
Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Alexander Egeberg¹, William Tillett², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…
Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Jan Brandt-Juergens¹, Martin Rudwaleit², Frank Behrens³, Christopher Ritchlin⁴, Daniel Peterlik⁵, Erhard Quebe-Fehling⁶, Renato Calheiros⁷ and Atul Deodhar⁸, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corp., Hoboken, NJ, ⁸Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
Abstract Number: 1259 • ACR Convergence 2022
Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
Thomas Leriche¹, Olivier Fakih², Clément Prati¹, Daniel Wendling³ and Frank Verhoeven⁴, ¹CHU de Besançon, Besançon, France, ²Service de rhumatologie, CHU de Besançon, Besançon, France, ³CHU, University Teaching Hospital, Besançon, France, ⁴Besançon University Hospital, Rheumatology Department, Besançon, France
Background/Purpose: Plaque Psoriasis (PsO) is an inflammatory disorder that could be associated with rheumatological manifestations defining Psoriatic arthritis. Moreover, recent studies showed that the presence…
Abstract Number: 1501 • ACR Convergence 2022
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
Isaac Cheng¹, Martin Li², Ho SO¹, Jack Lee², Chun Kwok Wong² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic Arthritis (PsA) is a complex, heterogeneous disease with chronic inflammation. Disease manifestations include the peripheral joint inflammation, dactylitis, enthesitis and skin psoriasis. Chronic…
Abstract Number: 1613 • ACR Convergence 2022
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Rachel Charlton¹, Laura Coates², James Galloway³, Neil McHugh¹, Anita McGrogan¹, Simon Hackett⁴, Melanie Brooke⁵ and William Tillett⁶, ¹University of Bath, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: To compare the time from symptom onset and General Practitioner (GP) presentation to referral and diagnosis for patients with psoriatic arthritis (PsA) to those…
Abstract Number: 2116 • ACR Convergence 2022
Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
Juan Josè de Agustin¹, Gustavo Añez¹, delia reina², Sergi Heredia³, Felipe Julio Ramirez Garcia⁴, Andrea Cuervo⁵, Jesus Rodriguez⁶, Carmen Moragues⁶, Patricia Moya⁷, Mireia Moreno⁸, Marta Arévalo⁸, Manel Pujol⁹, Georgina Salvador⁹, Noemi Busquets¹⁰, andres Ponce¹⁰, Ana Maria Laiz Alonso⁷ and MAria Pascual Pastor¹¹, ¹Vall D'hebron University Hospital, Barcelona, Spain, ²Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, ³Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, ⁴Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, ⁶Hospital Bellvitge, Hospitalet de Llobregat, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, ⁹Hospital Universitario MútuaTerrassa, Terrassa, Spain, ¹⁰Hospital General de Granollers, Granollers, Spain, ¹¹Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
Abstract Number: 2133 • ACR Convergence 2022
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
Oliver FitzGerald¹, Dafna Gladman², Philip J Mease³, Christopher Ritchlin⁴, Josef Smolen⁵, Lu Gao⁶, Sarah Hu⁶, Miroslawa Nowak⁶, Subhashis Banerjee⁶ and Ian M. Catlett⁶, ¹Conway Institute, University College Dublin, Dublin, Ireland, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Medical University of Vienna, Vienna, Austria, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].